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rostate cancer is the most common cancer among men worldwide.1
Moreover prostate adenocarcinoma is the most common noncutaneous
cancer diagnosed in men in the United States and the second leading
cause of cancer deaths.2 Despite the advances in the treatment of these pa-
tients in recent years, the rate of cardiovascular diseases among prostate can-
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The Influence of L-Carnitine in the Complex
Treatment of Patients with Renal Dysfunction
Who Have Synchronous Chronic Coronary Artery
Disease and Prostate Adenocarcinoma
ABS TRACT Objective: The aim of the study is to evaluate the effect of L-Carnitine on the dynamics of
inflammation, insulin resistance (IR), functional status of kidneys in the complex therapy of patients
with coronary heart disease (CHD) in combination with prostate adenocarcinoma and renal dysfunction.
Material and Methods: Forty two men with prostate adenocarcinoma and coronary heart disease were
enrolled. The patients were randomly and blindly divided into 2 groups: Group I patients were treated
with L-Carnitine in addition to standard treatment; Group II patients received only conventional treat-
ment. Standard laboratory blood tests, lipid profile, glucose, renal and liver function tests, serum C-re-
active protein (CRP), insulin, testosterone levels, echocardiographic examination were performed for all
patients at baseline and after 10 days of treatment. Results: Median level of HOMA index was 3.1 [1.9;
4.8] mg/ml. Insulin resistance  was established in 54.8% patients of Group I and 40% patients of control
group (p<0.05). In Group I, the mean insulin index and HOMA index decreased by 15.4% (p=0.001) and
19.2% (p=0.003), respectively. The supplementation of L-Carnitine in standard therapy contributed to
a significant decrease in serum creatinine level and an increase in the level of glomerular filtration rate
(GFR) in Group I patients (p<0.05). Conclusion: The supplementation of L-Carnitine in the complex
therapy of patients with coronary artery disease in combination with prostate adenocarcinoma con-
tributes to a significant decrease in insulin resistance, improves the functional state of kidneys. 
Keywords: Insulin resistance; carnitine; coronary disease; prostatic neoplasms 
ÖZET Amaç: Bu çalışmanın amacı koroner kalp hastalığı (KKH) olan hastalarda prostat adeno karsi-
nomu ve böbrek fonksiyon bozukluğu bulunması durumunda tedavide böbreklerin fonksiyonel du-
rumu, inflamasyon dinamikleri ve insülin direnci (IR) üzerinde L-Karnitinin etkisini değerlendirmektir.
Gereç ve Yöntemler: Prostat adenokarsinomu ve koroner kalp hastalığı olan 42 erkek alındı. Hastalar
randomize ve kör olarak 2 gruba ayrıldı: Grup I hastaları standart tedaviye ek olarak L-Karnitin ile te-
davi edildi; Grup II hastalar sadece geleneksel tedavi aldı. Bütün hastalar için standart laboratuvar kan
testleri, lipid profili, glukoz, böbrek ve karaciğer fonksiyon testleri, serum C-reaktif protein (CRP), in-
sülin, testosteron düzeyleri, ekokardiyografik inceleme bazal olarak ve 10 günlük tedavi sonrasında
yapıldı. Bulgular: Ortanca HOMA indeksi seviyesi 3,1 [1,9; 4,8] mg/ml. İnsülin rezistansı açılımı Grup
I’de %54,8, kontrol grubunda% 40 hastada saptandı (p<0,05). Grup I'de ortanca insülin indeksi ve
HOMA indeksi sırasıyla% 15,4 (p=0,001) ve %19,2 (p=0,003) azaldı. L-Karnitinin standart tedaviye ek-
lenmesi, Grup I hastalarında serum kreatinin seviyesinde anlamlı bir düşüşe ve glomerül filtrasyon
hızında bir artışa neden oldu (p<0,05). Sonuç: Koroner arter hastalığı olan hastaların prostat adeno-
karsinomu ile kombinasyon halinde kompleks tedavisinde L-Karnitin takviyesi, insülin direncinde
önemli bir düşüşe neden olur, böbreklerin fonksiyonel durumunu iyileştirir.
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cer cases is growing and leading to mortality. This
may be due to both the influence of the cancer itself
and the cancer treatment received. Nevertheless,
androgen deprivation therapy (ADT) reduces the
risk of mortality from prostate cancer, however, it’s
associated with the development of numerous ad-
verse metabolic effects and an increased risk of fatal
and/or nonfatal cardiovascular events.3-5 Given the
high clinical relevance, the European Society of
Cardiology (ESC) has issued a 2016 Position Paper
on Cancer Treatments and Cardiovascular Toxicity.
This document covers aspects of cardiovascular tox-
icity of anticancer treatment, providing expert opin-
ion for management and summarizing the most
important recommendations.6 But currently, there
are no recommendations for screening and primary
prophylaxis in patients with prostate cancer, who
have pre-existing cardiovascular diseases or those
who have a potential risk of cardiovascular morbid-
ity and mortality. Thus, the issues of early diagnosis
and primary prevention of coronary artery disease is
topic subject in patients with prostate adenocarci-
noma.
The heart-kidney axis is the focus of particular
attention in cardiac patients, even minimal renal
dysfunction is an important predictor of poor prog-
nosis in patients with chronic heart failure and
coronary artery disease.7 On the other hand, a de-
crease in GFR is an important prognostic factor in
oncology, particularily in patients with prostate
adenocarcinoma.8 Thus, this group of patients need
complex therapy to overcome cardiovascular risk
factors.
In the literature of recent years, more attention
is paid to drugs of metabolic correction in the treat-
ment of CAD, in particular L-Carnitine. L-Carnitine
plays an important role in the metabolism of fatty
acids, and its deficiency is common among cancer
patients receiving chemotherapy. Chemotherapy
inhibits specific membrane transport systems in
renal tubules with a consequent increase in the ex-
cretion of L-Carnitine and amino acids.9
Consequently, studies have shown that the ad-
ministration of L-Carnitine led to a significant re-
duction in both overall mortality and mortality due
to ventricular arrhythmia and/or acute myocardial
infarction (MI). In addition, there is evidence that
L-Carnitine can reduce the level of insulin-like
growth factor in diabetes mellitus and improve en-
dothelial function.10 It should be noted that there is
an evidence base for the clinical use of L-Carnitine
in chronic kidney disease patients receiving dialy-
sis therapy, in patients with cardiovascular, neuro-
logical diseases, etc.11-13 Particularly the recent
meta-analysis has demonstrated that L-Carnitine
treatment is effective for improving clinical symp-
toms and cardiac functions, decreasing serum lev-
els of B-type natriuretic peptide (BNP) and
N-terminal-pro-BNP in chronic heart failure
(CHF) patients.14
Thus, the recommendations of the American
Association of Cardiologists for the management of
patients with CHF note that the pharmacological
treatment of CHF can be supplemented with L-
Carnitine.15 On the other hand, recent studies have
shown that supplemental administration of L-Car-
nitine at a daily dose of 3 grams for 8 weeks is ef-
fective in preventing the side effects of
chemotherapy for neoplastic diseases, which gives
prospects for the use of this drug in patients with
combined cardio-oncological pathology.
The purpose of the study was to evaluate the
effect of L-Carnitine on the dynamics of inflam-
mation, insulin resistance, renal functional status
as part of the integrated therapy of patients with
CAD in combination with prostate adenocarci-
noma and renal dysfunction.
MATERIAL AND METHODS
The present study was conducted with approval
from the Ethics Committee according to the
principles outlined in the Helsinki declaration. All
participants of the research gave informed, written
consent. Dynamic observation and treatment were
performed in 42 men with prostate adenocarci-
noma and coronary artery disease (CAD) at the age
of 45 to 75 years (main group). The control group
consisted of 20 men with coronary artery disease
and prostatic hyperplasia, comparable in age, car-
diovascular risk profile, received treatment for
coronary artery disease and didn’t get L-Carnitine
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infusion. Baseline characteristics of the study pa-
tients have been demonstrated in Table 1.
All patients had CAD according to the classifi-
cation of the the European Society of Cardiology, the
diagnosis of prostate adenocarcinoma was verified.
Among the forms of CAD, stable angina prevailed
in 25 patients (59.5%), the remaining 17 patients
(40.5%) had post-infarction cardiosclerosis. 
During follow-up, all patients received CAD
and prostate cancer treatment which did not
change during the whole observation period.
Inclusion criteria were: being aged 45-75 years,
the presence of a verified diagnosis of prostate ade-
nocarcinoma, consistently selected anticancer ther-
apy for 6 months, the presence of a verified
diagnosis of coronary artery disease, consistently se-
lected cardiac therapy for the last 3 months, volun-
tary informed consent to participate in the study.
Exclusion criteria included age over 75 years,
the presence of metastatic lesions, chronic heart
failure with low ejection fraction (EF), arrhythmias
that cause hemodynamic disturbances and require
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Characteristic Main group (n=42) Control group (n=20)
Median of age, years 65 [59; 73] 63.6 [57; 71.5]
Median duration of CAD, years 10.3 [7.4; 18.4] 10.1 [7.1; 18.2]
Median duration of prostate сancer, years 5.8 [2.5; 7.8] 5.5 [2.4; 7.5]
Glomerular filtration rate (GFR), ml / (min • 1.73 m2) 74 [61; 79] 77 [63; 82]
Patients with GFR <60 ml / min. / 1.73 m2, % 31 15
Patients with GFR <90 ml / min. / 1.73 m2, % 100 90
Median testosterone level, ng / ml 1.4 [0.8; 2.5] 1.6 [0.9; 2.7]
Patients with decreased testosterone level, % 45.2 20
Patients with hypertension, % 83.3 80
Patients with CHF (%):
I functional class (FC)
II functional class
54.8 50
16.7 20
83.3 80
Median of ejection fraction, % 64.4 [52.4; 69.3] 66.2 [53.8; 70.8] 
Patients with reduced ejection fraction, % 14.3 10
Patients, received cardiology treatment (%): 
ACE inhibitors
ACE receptors blockers
β-blockers 
calcium antagonists 
statins 
antiplatelet agents 
81 80
16 15
81 75
73.8 70
69 60
57.1 50
Patients, received oncology treatment (%):
ADT
surgical treatment
combined treatment
61.9 -
57.1 -
47.6 -
TABLE 1: Baseline characteristics of the study patients.
correction with antiarrhythmic agents (including
high gradations of ventricular arrhythmias, atrial
flutter, paroxysmal tachycardias, sinus node weak-
ness syndrome, atrio-ventricular (AV) blockade 2-
3 degrees), acute myocardial infarction (MI), acute
cerebrovascular accident, diabetes, hyper- and hy-
pothyroidism with TTG levels> 10 mU/l, chronic
renal insufficiency [glomerular filtration rate
(GFR) <30 ml/ min./1.73 m2], acute cardiac and
renal failure, obesity with grade 4, cachexia.
Patients were blindly divided into two groups:
Group I (n=20)-CAD patients in combination with
prostate adenocarcinoma and renal dysfunction,
who received L-Carnitine (Metakartin, World
Medicine, MefarIlac San. A.S.) intravenously with
100 ml of 0.9% NaCl once daily for 10 days in ad-
dition to standard therapy. Group II (n=22)-pa-
tients who were treated with standard regimen
without L-Carnitine prescription.
In the initial state, the patients of both groups
were comparable in terms of the main disease, in-
dicators of gender, age, duration of the disease,
level of GFR, systolic and diastolic blood pressure,
heart rate. 
In order to determine the effectiveness and
safety of exposure to L-Carnitine depending on the
hormone sensitivity of prostate adenocarcinoma,
patients of Group I are divided into subgroups: Ia
(n=11)-CAD patients in combination with hor-
mone-sensitive prostate adenocarcinoma and Ib
(n=9)-patients with CAD in combination with hor-
mone-insensitive prostate adenocarcinoma, which
were comparable in the main indicators.
To solve the problems of the study, all patients
were determined by objective and subjective signs
inherent in CAD, they conducted anamnestic data
collection, physical examination and laboratory and
instrumental methods at the beginning and at the
end of the study. The duration of observation in the
hospital was 10 days, then the patients were ob-
served at outpatient setting. The survey included:
standard clinical and biochemical laboratory tests
(clinical study of blood, urine, daily proteinuria
level; biochemical blood test: creatinine, urea, ALT,
AST, blood lipid spectrum), immunoassay for blood
tests for insulin, C-reactive protein (CRP), ra-
dioisotope blood test with determination of testos-
terone levels; electrocardiography (ECG), Doppler
echocardiography. Glomerular filtration rate was
determined by the formula CKD-EPI, insulin re-
sistance (IR)-by the formula HOMA.16 Tolerability
of the drug was determined on the basis of an as-
sessment of laboratory parameters (serum ALT,
AST levels), the level of GFR, the incidence of ad-
verse reactions.
Statistical processing of the obtained results
was performed using the licensed program STA-
TISTICS. Non-parametric statistics were used. The
data was presented in the form of a median (Me)
and the interquartile segment [25%; 75%]. For
comparison of indicators in two independent
groups, the Mann-Whitney U-test, the two-sided
Fisher exact test, and the Wilcoxon test (W) were
used to compare two dependent groups. Statisti-
cally significant differences in research results were
determined at a level of p<0.05.
RESULTS
The level of insulin in patients with coronary heart
disease on the background of prostate adenocarci-
noma ranged from 8.6 to 22.2 MO/ml baseline, the
median was 10.7 [6.9; 15.7] MO/ml, in the control
group 8.2 [4.8; 11.0] MO/ml respectively (p=0.003).
Insulin resistance was established in 23 (54.8%) pa-
tients of main group and 8 (40%) of controls
(p<0.05). It was found that patients in the main
group had a significantly higher level of HOMA
index compared with the control group (p <0.05),
with the highest level of IR observed in patients
with a hormone-sensitive form of the prostate ade-
nocarcinoma (Table 2). Correlation relations be-
tween the HOMA index in patients with the main
group and age, GFR, body mass index (BMI) were
determined-R=-0.48 (p <0.05), R=-0.62 (p<0.05),
R=0, 66 (p<0.05) respectively.
Analysis of the dynamics of the insulin level
and insulin resistance on the background of treat-
ment revealed significant differences in these indi-
cators in patients of the  Group I and Group II
(Figure 1). In the group of patients to whom L-Car-
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nitine was included in the composition of complex
therapy, the mean insulin index and HOMA index
decreased by 15.4% (p=0.001) and 19.2% (p=0.003),
respectively, in the standard treatment group these
indicator dynamics were not significantly different.
The supplementation of L-Carnitine in the complex
therapy contributed to a more pronounced decrease
in IR in patients with ischemic heart disease in
combination with the hormone-sensitive form of
prostate adenocarcinoma (Figure 2).
It was established that the supplementation of
L-Carnitine in standard therapy contributed to a
significant decrease in serum creatinine level and
an increase in the level of GFR in Group I patients
(Figure 3).
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FIGURE 1: Dynamics of insulin resistance in patients depending of L-Сarnitine supplementation. Notes; * Significance of differences at the beginning and end
of observation, p <0.05 (according to the Wilcoxon test). # Significance of differences compared with group 2, p <0.05 (according to Man-Whitney test).
Indicators
All patients
(СAD + prostate adenocarcinoma)
(n=42)
Group I
(СAD + hormone-sensitive
prostate adenocarcinoma)
(n=20)
Group II
(СAD + hormone-insensitive
prostate adenocarcinoma)
(n=22)
Control group 
(СAD+ prostatic hyperplasia)
(n=20)
Іnsulin, ОD/ml 10.7 [6.9; 15.7] 12.4 [8.2; 17.2]# 10.1 [6.2; 12.1]* 7.7 [2.9; 9.3]
НОМА 3.1 [1.9; 4.8] 3.4 [1.8; 5.2]# 2.8 [2.1; 3.3]* 1.8 [1.0; 2.5]
TABLE 2: Level of insulin, insulin resistance in patients with coronary heart disease in prostate
adrenocarcinoma  depending on hormone sensitivity.
Notes: * - Significance of the differences between the Ia and the Ib subgroups; # - Significance of the differences with the control group.
FIGURE 2: Dynamics of insulin resistance in patients of the main group depending on the hormone sensitivity. Notes; * Significance of differences at the beginning and
at the end of the observation, p <0.05 (according to the Wilcoxon test). # Significance of differences compared with group 2, p <0.05 (according to Mann-Whitney test).
At the beginning of the study, the level of CRP
in patients with CAD on the background of
prostate adenocarcinoma ranged from 4.1 to 12.5
mmol/ml, the median was 10.3 [5.2; 11.1] OD/ml,
in the control group-7.4 [3.1; 8.6] mmol/ml, re-
spectively (p=0.0002), there were no significant dif-
ferences depending on hormone sensitivity.
Increased CRP level was established in 26 (61.9%)
patients of main group and 9 (45%) of controls
(p<0.05). Correlations between the indicator of
CRP in patients of the main group of GFR, BMI-
R=-0.52 (p<0.05), R=0.61 (p<0.05), respectively,
were determined. In the group of patients to whom
L-Carnitine was included in the complex therapy,
a tendency to a decrease in the average CRP was
found (p = 0.056), in the standard treatment group,
these indicators did not differ significantly in dy-
namics (Figure 4).
There were no significant side effects with the
inclusion of L-Carnitine to the standard therapy in
the dynamics of observation, and was no need to
change the daily dose or discontinue treatment.
The supplementation of L-Carnitine in the com-
plex treatment contributed to a significant im-
provement in exercise tolerance according to the
test results with a six-minute walk. At the end of
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FIGURE 3: Dynamics of GFR in patients of the main group. Notes;  * Significance of differences at the beginning and end of observation, p <0.05 (according to
the Wilcoxon test). # Significance of differences compared with group 2, p <0.05 (according to Mann-Whitney test).
FIGURE 4: Dynamics of CRP in patients of the main group depending of L-Сarnitine supplementation.
the observation, the levels of ALT, AST, bilirubin
did not change significantly compared with the ini-
tial state.
DISCUSSION
Cardio-oncology, which includes all aspects of the
relationship between cardiovascular and malignant
disease, is an area of increasing interest in clinical
practice. However, there are less frequent and less
well-known interactions, such as induction and ag-
gravation of atherosclerosis by chemotherapy and
radiation.
As known, the pathogenesis of atherosclerosis
in oncological patients is complex and depends on
multiple cardiovascular factors. Search for thera-
peutic options of cardiovascular risk correction to
improve prognosis in patients with CAD and
prostate adenocarcinoma remains topical. Ameri-
can College of Cardiology Foundation/American
Heart Association (ACCF/AHA) recommendations
note that a number of toxic agents may lead to left
ventricle dysfunction and CHF. Particularly, the
deficiency in L-Carnitine may be associated with a
syndrome of progressive skeletal myopathy and
cardiomyopathy.17,18 Thus, L-Carnitine may be use-
ful in patients with toxic injuries, particularly in
oncology profile patients.
The recent meta-analysis performed by Ying
Xu and al. demonstrated that the L-Carnitine was
useful in treating patients with IR with more ef-
fectively for prolonging the medication time.19
Thus, the result of 5 studies showed L-Carnitine
was effective in the treatment of IR (WMD-0.724,
CI-0.959-0.488, p<0.0001), evaluation at 3, 6, 9, 12
months, the p-values were 0.875, 0.165, 0.031, 0,
007, respectively.19 Our research showed that the
use of L-Carnitine (Metakartin, World Medicine,
MefarIlac San. A.S.) at a dose of 2 g (10 ml) intra-
venously for 10 days causes an additional positive
clinical effect with a significant decrease in IR on
19.2% (p=0.003) in the complex therapy of patients
with CAD with prostate adenocarcinoma. How-
ever, RCTs with long-term L-Carnitine treatment
of IR are needed to confirm the viewpoint for this
population of patients.
The overall findings of another meta-analysis
has found the clinically relevant benefit of L-Car-
nitine supplementation in lowering the circulating
levels of CRP.17 In this meta-analysis the obtained
combined weighted mean reduction in CRP con-
centrations was-0.39 mg/L [95% CI (-0.62- -0.16)].
The present study results demonstrated a tendency
in CRP level decrease with maximum effect in the
group of patients with hormone-sensitive prostate
adenocarcinoma. In this way it could be perspecti-
val to evaluate CRP dynamics with prolongation of
L-Carnitine therapy in patients with CAD and
prostate adenocarcinoma.
Data are available indicating that reduced cir-
culating and tissue carnitine levels, possibly lead to
impaired mitochondrial function, have been pos-
tulated to be involved in the pathogenesis of insulin
resistance, kidney dysfunction. Thus, this assump-
tions could explain obtained results. The estab-
lished data determine the feasibility of further
research to clarify the mechanisms of L-Carnitine
infusion to carbohydrate metabolism, systemic in-
flammation, and kidney function in patients with a
cardio-oncology profile.
LIMITATIONS
However, the results of this study should be inter-
preted with caution because of several limitations.
Therefore, only patients with stable angina and post-
infarction cardiosclerosis on prostate adenocarci-
noma were chosen for this study, and consequently
the results can only be applied to this population. It
should be noted that there is no oral L-Carnitine for
continuation treatment after administering it intra-
venously. It could be perspectival to evaluate the
hard end point with prolongation of this therapy.
CONCLUSION
In the majority of patients with coronary artery
disease in combination with prostate adenocarci-
noma, relevance was established to insulin resist-
ance, laboratory indicators of systemic inflam-
mation associated with obesity age and renal func-
tion. The supplementation of L-Carnitine in the
complex therapy of patients with coronary artery
disease in combination with prostate adenocarci-
Oksana SIRENKO et al. Tur ki ye Kli nik le ri J Med Sci. 2019;39(4):381-8
387
noma and renal dysfunction contributes to a sig-
nificant decrease in insulin resistance, improves the
functional state of the kidneys and is well tolerated.
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